Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
NCT03343678 · Boehringer Ingelheim · PHASE1 · withdrawn · last registry update 2018-01-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Company strategic decision” | – | Registry record, Boehringer Ingelheim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-12-07Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Bevacizumab (NCT03768063)
- 2018-11-13Phase 3 first posted: National Cancer Institute (NCI), Ibrutinib + Obinutuzumab (NCT03737981)
- 2018-10-10Phase 3 first posted: National Cancer Institute (NCI), Ibrutinib + Obinutuzumab (NCT03701282)
- 2018-03-12Phase 3 first posted: Janssen Research & Development, LLC, Ibrutinib + Venetoclax (NCT03462719)
- 2017-03-03Phase 3 first posted: AbbVie, Placebo + Venetoclax (NCT03069352)
- 2017-01-09Phase 3 first posted: Beat AML, LLC, Samalizumab (BAML-16-001-S1) + BI 836858 (BAML-16-001-S2) (NCT03013998)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision